Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Change in Acquisitions & Divestments (2020 - 2025)

Maxcyte (MXCT) has disclosed Change in Acquisitions & Divestments for 6 consecutive years, with $40.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 6.98% to $40.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $148.6 million, a 23.67% decrease, with the full-year FY2024 number at $159.4 million, down 49.19% from a year prior.
  • Change in Acquisitions & Divestments was $40.0 million for Q3 2025 at Maxcyte, up from $31.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $200.8 million in Q1 2022 to a low of $6.0 million in Q3 2021.
  • A 5-year average of $52.9 million and a median of $44.8 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: surged 1154.97% in 2022, then tumbled 61.29% in 2024.
  • Maxcyte's Change in Acquisitions & Divestments stood at $55.5 million in 2021, then dropped by 5.41% to $52.5 million in 2022, then increased by 26.19% to $66.2 million in 2023, then crashed by 53.21% to $31.0 million in 2024, then rose by 29.03% to $40.0 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Change in Acquisitions & Divestments are $40.0 million (Q3 2025), $31.0 million (Q2 2025), and $46.6 million (Q1 2025).